Hepatitis C Virus

Modified siRNA compuund selected for development in hepatitis C antiviral program

Published in Hepatitis Weekly, January 23rd, 2006

Sirna Therapeutics, Inc. (RNAI), a clinical-stage RNAi therapeutics company, announced that it has selected Sirna-AV34, a systemically delivered, chemically modified short interfering RNA (siRNA) compound, as its candidate for advancement to human clinical testing against hepatitis C virus.

Sirna completed its preclinical evaluation of the efficacy of Sirna-AV34 and has begun cGMP manufacturing for its phase 1 clinical studies. Sirna expects to initiate IND-enabling toxicology studies in the first quarter of 2006 followed by the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA).

Sirna-AV34 is a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry